Clinical updates in adult immune thrombocytopenia

Blood

Volumn 129, Issue 21, 2017, Pages 2829-2835

  Lambert, Michele P ^a   Gernsheimer, Terry B ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT DISEASE; BLEEDING; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; META ANALYSIS (TOPIC); NONHUMAN; PATIENT CARE; PREGNANCY DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPLENECTOMY; ADULT; AGONISTS; BLOOD; HEMORRHAGE; MALE; METABOLISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; THROMBOCYTE COUNT;

MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

ADULT; FEMALE; HEMORRHAGE; HUMANS; MALE; PLATELET COUNT; PRACTICE GUIDELINES AS TOPIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; SPLENECTOMY;

EID: 85019653116     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-03-754119     Document Type: Review

References (98)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. 2009;113(11): 2386-2393.
2. Schulze H, Gaedicke G. Immune thrombocytopenia in children and adults: What's the same, what's different? Haematologica. 2011; 96(12):1739-1741.
3. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
4. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2): 168-186.
5. Michel M. Immune thrombocytopenia nomenclature, consensus reports, and guidelines: What are the consequences for daily practice and clinical research? Semin Hematol. 2013; 50(suppl 1):S50-S54.
6. Fogarty PF. Chronic immune thrombocytopenia in adults: Epidemiology and clinical presentation. Hematol Oncol Clin North Am. 2009;23(6): 1213-1221.
7. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol. 2009;145(2):235-244.
8. Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: A nationwide population-based study in France. Blood. 2014; 124(22):3308-3315.
9. Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Thromboembolism in adults with primary immune thrombocytopenia: A systematic literature review and meta-Analysis. Eur J Haematol. 2016;97(4):321-330.
10. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
11. Frederiksen H, Maegbaek ML, Nørgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: A Danish population-based cohort study. Br J Haematol. 2014;166(2):260-267.
12. Thai LH, Mahevas M, Roudot-Thoraval F, et al. Long-Term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore). 2016;95(48):e5098.
13. Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci. 1965;124(2): 499-542.
14. Khodadi E, Asnafi AA, Shahrabi S, Shahjahani M, Saki N. Bone marrow niche in immune thrombocytopenia: A focus on megakaryopoiesis. Ann Hematol. 2016;95(11):1765-1776.
15. Olsson B, Andersson PO, Jernas M, et al. T-cellmediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-1124.
16. Zhang HY, Hou M, Zhang XH, Guan XH, Sun GZ. The diagnostic value of platelet glycoproteinspecific autoantibody detection in idiopathic thrombocytopenic purpura [in Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004; 12(2):204-206.
17. Cines DB, Cuker A, Semple JW. Pathogenesis of immune thrombocytopenia. Presse Med. 2014; 43(4 Pt 2):e49-e59.
18. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000;96(7):2520-2527.
19. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003; 102(3):887-895.
20. Leytin V, Mykhaylov S, Starkey AF, et al. Intravenous immunoglobulin inhibits antiglycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol. 2006;133(1):78-82.
21. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010;95(7): 1167-1175.
22. Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: A Danish population-based cohort study. Br J Haematol. 2011;152(3):360-362.
23. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998; 102(7):1393-1402.
24. Nishimoto T, Kuwana M. CD41CD251Foxp31 regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol. 2013;50(suppl 1):S43-S49.
25. Qiu J, Liu X, Li X, et al. CD8(1) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Sci Rep. 2016;6:27445.
26. Zhao C, Li X, Zhang F, Wang L, Peng J, Hou M. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica. 2008;93(9): 1428-1430.
27. Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood. 2008; 112(4):1078-1084.
28. Baeten DL, Kuchroo VK. How cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nat Med. 2013;19(7): 824-825.
29. Ma D, Zhu X, Zhao P, et al. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol. 2008; 87(11):899-904.
30. Rocha AM, Souza C, Rocha GA, et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica. 2011;96(10):1560-1564.
31. Ware RE, Howard TA. Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura. Blood. 1993;82(7): 2137-2142.
32. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: Increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146(6):585-596.
33. Malara A, Abbonante V, Di Buduo CA, Tozzi L, Currao M, Balduini A. The secret life of a megakaryocyte: Emerging roles in bone marrow homeostasis control. Cell Mol Life Sci. 2015; 72(8):1517-1536.
34. Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol. 2013;88(12): 1041-1044.
35. Hoffmeister KM. The role of lectins and glycans in platelet clearance. J Thromb Haemost. 2011; 9(suppl 1):35-43.
36. Rumjantseva V, Hoffmeister KM. Novel and unexpected clearance mechanisms for cold platelets. Transfus Apheresis Sci. 2010;42(1): 63-70.
37. Hoffmeister KM, Falet H. Platelet clearance by the hepatic Ashwell-Morrell receptor: mechanisms and biological significance. Thromb Res. 2016; 141(suppl 2):S68-S72.
38. Jansen AJ, Josefsson EC, Rumjantseva V, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIba metalloproteinase-mediated cleavage in mice. Blood. 2012;119(5):1263-1273.
39. Jansen AJ, Peng J, Zhao HG, Hou M, Ni H. Sialidase inhibition to increase platelet counts: A new treatment option for thrombocytopenia. Am J Hematol. 2015;90(5):E94-E95.
40. Alioglu B, Tasar A, Ozen C, Selver B, Dallar Y. An experience of oseltamivir phosphate (tamiflu™) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: A case report. Pathophysiol Haemost Thromb. 2010;37(2-4): 55-58.
41. Shao L, Wu Y, Zhou H, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody. Platelets. 2015; 26(5):495-497.
42. Purohit A, Aggarwal M, Singh PK, et al. Reevaluation of need for bone marrow examination in patients with isolated thrombocytopenia contributors [published correction appears in Indian J Hematol Blood Transfus. 2016;32(2): 197]. Indian J Hematol Blood Transfus. 2016; 32(2):193-196.
43. Altintas A, Ozel A, Okur N, et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis. 2007;24(2): 163-168.
44. Li HQ, Zhang L, Zhao H, Ji LX, Yang RC. Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: A retrospective single-centered analysis of 1791 cases. Chin Med J (Engl). 2005; 118(1):34-37.
45. Abbasi SY, Milhem M, Zaru L. A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura. Ann Hematol. 2008;87(6):459-462.
46. Melboucy-Belkhir S, Khellaf M, Augier A, et al. Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. Am J Hematol. 2016;91(12):E499-E501.
47. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991;77(1): 31-33.
48. Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: A systematic review. J Thromb Haemost. 2015;13(3): 457-464.
49. Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR; Intercontinental Childhood ITP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: An observational study. Lancet. 2001;358(9299): 2122-2125.
50. Grimaldi- Bensouda L, Nordon C, Michel M, et al; Group for the PGRx-ITP Study. Immune thrombocytopenia in adults: A prospective cohort study of clinical features and predictors of outcome. Haematologica. 2016;101(9): 1039-1045.
51. Altomare I, Cetin K, Wetten S, Wasser JS. Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: A retrospective cohort study using a large administrative medical claims database in the US. Clin Epidemiol. 2016;8:231-239.
52. Schiavotto C, Rodeghiero F. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: Results in 490 cases. Haematologica. 1993; 78(6 suppl 2):22-28.
53. Middelburg RA, Carbaat-Ham JC, Hesam H, Ragusi MA, Zwaginga JJ. Platelet function in adult ITP patients can be either increased or decreased, compared to healthy controls, and is associated with bleeding risk. Hematology. 2016; 21(9):549-551.
54. Panzer S, Rieger M, Vormittag R, Eichelberger B, Dunkler D, Pabinger I. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest. 2007;37(10): 814-819.
55. Cuker A, Cines DB, Neunert CE. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol. 2016;23(5):479-485.
56. Matschke J, Müller-Beissenhirtz H, Novotny J, et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-näive adult patients with immune thrombocytopenia: EIS 2002 Study. Acta Haematol. 2016;136(2): 101-107.
57. Din B, Wang X, Shi Y, Li Y. Long-Term effect of high-dose dexamethasone with or without lowdose dexamethasone maintenance in untreated immune thrombocy topenia. Acta Haematol. 2015; 133(1):124-128.
58. Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: A prospective multicenter randomized trial. Blood. 2016;127(3): 296-302, quiz 370.
59. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14): 2755-2762.
60. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121(11): 1976-1981.
61. Choi PY, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015; 126(4):500-503.
62. Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: Final results from a phase 2 study. Br J Haematol. 2016;172(2): 262-273.
63. Gómez-Almaguer D, Herrera-Rojas MA, Jaime-Pérez JC, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014; 123(25):3906-3908.
64. Palandri F, Polverelli N, Sollazzo D, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016;91(4): E267-E272.
65. Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-Term results and treatment of postsplenectomy relapses. Ann Hematol. 2002; 81(6):312-319.
66. Ahmed R, Devasia AJ, Viswabandya A, et al. Long-Term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : Splenectomy in ITP. Ann Hematol. 2016;95(9):1429-1434.
67. Guan Y, Wang S, Xue F, et al. Long-Term results of splenectomy in adult chronic immune thrombocytopenia. Eur J Haematol. 2017;98(3): 235-241.
68. Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: A systematic review and meta-Analysis. Lancet Haematol. 2015;2(2):e75-e81.
69. Ghanima W, Khelif A, Waage A, et al; RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): A multicentre, randomised, double-blind, placebocontrolled trial. Lancet. 2015;385(9978): 1653-1661.
70. Elgebaly AS, Ashal GE, Elfil M, Menshawy A. Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-Analysis of randomized controlled trials [published online ahead of print 1 January 2016]. Clin Appl Thromb Hemost. 2016.
71. Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015;32(10):875-887.
72. Mazza P, Minoia C, Melpignano A, et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): A "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol. 2016;95(2):239-244.
73. Gonźalez-Ĺopez TJ, Alvarez-Roḿan MT, Pascual C, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016;97(3): 297-302.
74. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16):4338-4345.
75. Gonźalez-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169(1):111-116.
76. Saleh MN, Bussel JB, Cheng G, et al; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-Term, open-label EXTEND study. Blood. 2013;121(3): 537-545.
77. Saleh M, Bussel JB, Wong R, et al. Hepatobiliary and thromboembolic events during long-Term E.X.T.E.N.Ded treatment with eltrombopag in adult patients with chronic immune thrombocytopenia [abstract]. Blood. 2016; 128(12).
78. Cines DB, Gernsheimer T, Wasser J, et al. Integrated analysis of long-Term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015;102(3): 259-270.
79. Shih A, Nazi I, Kelton JG, Arnold DM. Novel treatments for immune thrombocytopenia. Presse Med. 2014;43(4 Pt 2):e87-e95.
80. Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood. 2004;103(4): 1229-1236.
81. Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008;141(4): 545-548.
82. Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood. 2012;120(18):3670-3676.
83. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113(14):3154-3160.
84. Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887-3894.
85. Fan H, Zhu HL, Li SX, et al. Efficacy of amifostine in treating patients with idiopathic thrombocytopenia purpura. Cell Biochem Biophys. 2011;59(1):7-12.
86. Kelton JG. Idiopathic thrombocytopenic purpura complicating pregnancy. Blood Rev. 2002;16(1): 43-46.
87. American College of Obstetricians and Gynecologists. ACOG practice bulletin: Thrombocytopenia in pregnancy. Number 6, September 1999. Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet. 1999;67(2):117-128.
88. Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood. 2003;102(13): 4306-4311.
89. Loustau V, Debouverie O, Canoui-Poitrine F, et al. Effect of pregnancy on the course of immune thrombocytopenia: A retrospective study of 118 pregnancies in 82 women. Br J Haematol. 2014; 166(6):929-935.
90. Al-Jama FE, Rahman J, Al-Suleiman SA, Rahman MS. Outcome of pregnancy in women with idiopathic thrombocytopenic purpura. Aust N Z J Obstet Gynaecol. 1998;38(4):410-413.
91. Wyszynski DF, Carman WJ, Cantor AB, et al. Pregnancy and birth outcomes among women with idiopathic thrombocytopenic purpura. J Pregnancy. 2016;2016:8297407.
92. Nicolescu A, Vladareanu AM, Voican I, Onisai M, Vladareanu R. Therapeutic options for immune thrombocytopenia (ITP) during pregnancy. Maedica (Buchar). 2013;8(2):182-188.
93. Samuelson B, Baumann Kreuziger L, Gernsheimer T. Use of romiplostim for refractory primary immune thrombocytopenia during pregnancy. Clinical Obstetrics, Gynecology and Reproductive Medicine. COGRM; 2017.
94. Kong Z, Qin P, Li H, et al. A multicenter openlabeled pilot study on recombinant human thrombopoietin in the management of immune thrombocytopenia in pregnancy [abstract]. Blood. 2016;128(22).
95. Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013; 121(1):38-47.
96. Dan U, Barkai G, David B, Goldenberg M, Kukkia E, Mashiach S. Management of labor in patients with idiopathic thrombocytopenic purpura. Gynecol Obstet Invest. 1989;27(4): 193-196.
97. Goodier CG, Lu JT, Hebbar L, Segal BS, Goetzl L. Neuraxial anesthesia in parturients with thrombocytopenia: A multisite retrospective cohort study. Anesth Analg. 2015;121(4): 988-991.
98. van der Lugt NM, van Kampen A, Walther FJ, Brand A, Lopriore E. Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura. Vox Sang. 2013;105(3): 236-243.